The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer

The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer

<p>Abstract</p> <p>Background</p> <p>Over recent years a number of novel therapies have shown promise in advanced renal cell carcinoma (RCC). Internationally the standard of care of first-line therapy is sunitinib™, after a clear survival benefit was demonstrated over i...

Full description

Bibliographic Details
Main Authors: Collinson Fiona J, Gregory Walter M, McCabe Chris, Howard Helen, Lowe Catherine, Potrata DrBarbara, Tubeuf Sandy, Hanlon Pat, McParland Lucy, Wah T, Selby Peter J, Hewison Jenny, Brown Julia, Brown Janet
Format: Article
Language:English
Published: BMC 2012-12-01
Series:BMC Cancer
Subjects:
Renal cancer
Sunitinib
Intermittent treatment
Quality of life
Quality adjusted life years
Health economics
Online Access:http://www.biomedcentral.com/1471-2407/12/598

Internet

http://www.biomedcentral.com/1471-2407/12/598

Similar Items